Amgen's Neulasta banner draws OPDP’s second letter of 2021

In its second enforcement letter of 2021, the US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) flagged issues with Amgen’s promotion of its biological product Neulasta (pegfilgrastim) in a banner ad intended for healthcare professionals.